EDIT
Price
$2.62
Change
+$0.10 (+3.97%)
Updated
Oct 2 closing price
Capitalization
385.49M
37 days until earnings call
Intraday BUY SELL Signals
SMMT
Price
$16.75
Change
+$0.06 (+0.36%)
Updated
Oct 2 closing price
Capitalization
12.35B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs SMMT

EDIT vs SMMT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. SMMT commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and SMMT is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
EDIT vs SMMT: Fundamental Ratings
EDIT
SMMT
OUTLOOK RATING
1..100
6194
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
90
Overvalued
PROFIT vs RISK RATING
1..100
10074
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8143
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for SMMT (90). This means that EDIT’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as EDIT (100). This means that SMMT’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as SMMT (100). This means that EDIT’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for EDIT (81). This means that SMMT’s stock grew somewhat faster than EDIT’s over the last 12 months.

SMMT's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that SMMT’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITSMMT
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
84%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (EDIT: $2.62 vs. SMMT: $16.75)
Brand notoriety: EDIT and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 79% vs. SMMT: 80%
Market capitalization -- EDIT: $385.49M vs. SMMT: $12.35B
EDIT [@Biotechnology] is valued at $385.49M. SMMT’s [@Biotechnology] market capitalization is $12.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while SMMT’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, SMMT is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while SMMT’s TA Score has 6 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 6 bearish.
  • SMMT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SMMT is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а +1.55% price change this week, while SMMT (@Biotechnology) price change was +7.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

SMMT is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
SMMT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AVT106.934.69
+4.59%
Avnet
FIP2.680.08
+3.27%
FTAI Infrastructure
HGBL1.290.03
+2.38%
Heritage Global
LOB36.680.29
+0.80%
Live Oak Bancshares
XSLLU10.17N/A
N/A
Xsolla SPAC 1

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
-1.30%
BCDA - SMMT
70%
Closely correlated
+0.99%
KURA - SMMT
42%
Loosely correlated
-0.56%
VKTX - SMMT
41%
Loosely correlated
-6.41%
EDIT - SMMT
40%
Loosely correlated
-1.95%
SNDX - SMMT
39%
Loosely correlated
-3.09%
More